Regulations.gov document
Solvotrin Therapeutics- Active Iron High Potency- supports the formation of haemoglobin…
Other · FDA-2018-S-0024 · posted Oct 18, 2018
Key facts
| Document ID | FDA-2018-S-0024-0658 |
|---|---|
| Title | Solvotrin Therapeutics- Active Iron High Potency- supports the formation of haemoglobin and red blood cells |
| Document type | Other |
| Subtype | 30 Day Structured Function Claim |
| Agency | FDA |
| Docket | FDA-2018-S-0024 |
| Posted | Oct 18, 2018 |
| Comment period opens | Oct 18, 2018 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: